Investigating the Effectiveness of Vimida
← catalyst calendarSponsored by Gaia AG (industry) · GAIA — their whole pipeline →. With Medical School Hamburg, Institut Long-Covid Rostock.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
160estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-13 | actual | When the study began enrolling |
| Primary completion | Sep 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Long COVID
- Post COVID-19 Condition
Intervention
- Behavioral: vimida
Primary outcome
what the primary-completion date above is the date OFFatigue symptom severity
measured 3 months
Permalink · GAIA's whole pipeline · Catalyst calendar · Every registered study · What changed